Brain GAP: The MISDIAGNOSIS
Brain GAP: The MISDIAGNOSIS AUTHOR: KJ Lavan We are misdiagnosing the problem in brain health. Everyone is focused on innovation. New drugs. New biomarkers. Earlier detection. And yes, the science is moving fast. Lecanemab and donanemab have shifted Alzheimer’s care from symptom management toward disease modification in early-stage disease. But 2025 appropriate-use recommendations for donanemab make clear that treatment requires biomarker confirmation, careful patient selection, MRI monitoring, and structured clinical pathways. ( ScienceDirect ) Blood-based biomarkers are also accelerating the field. A 2025 Nature Medicine study showed that automated plasma p-tau217 testing can identify Alzheimer’s pathology with high accuracy, while also emphasizing the need for two-cutoff approaches across real-world settings. ( Nature ) A 2025 JAMA Neurology cohort study of nearly 3,000 cognitively unimpaired individuals found that plasma p-tau217 can help identify...